Bicara Therapeutics Stock

www.bicara.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $710.05MM

Bicara Therapeutics, founded in 2020, is a clinical-stage company striving to develop biologics for cancer patient treatments. Bicara uses tumor-targeting antibodies and the tumor-microenvironment aiming to impact the tumor site for a hardwearing effect. Working to advance cancer treatment for patients who have had difficulty with first- and second-line therapies, Bicara partners with chemistry, manufacturing, and controls (CMC) experts and professional protein engineers who have a history of progressing FDA-approved drugs. Bicara Therapeutics is headquartered in Cambridge, Massachusetts.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Bicara Therapeutics before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Bicara Therapeutics Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Bicara Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
12/12/2023 Series C $165MM $xx.xx $495.55MM Acorn Bioventures, Aisling Capital, Bioqube Ventures, Braidwell Lp, Deerfield Management, Eight Roads Ventures, Fairmount, F-Prime Capital, Invus Piper Heartland Healthcare Capital, Janus Henderson Investors, Omega Funds, Premji Invest, Ra Capital Management, Red Tree Venture Capital, The Rise Fund, Tpg
Price per Share
$xx.xx
Shares Outstanding
119,599,872
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acorn Bioventures, Aisling Capital, Bioqube Ventures, Braidwell Lp, Deerfield Management, Eight Roads Ventures, Fairmount, F-Prime Capital, Invus Piper Heartland Healthcare Capital, Janus Henderson Investors, Omega Funds, Premji Invest, Ra Capital Management, Red Tree Venture Capital, The Rise Fund, Tpg
03/06/2023 Series B $108.23MM $xx.xx $274.39MM Acorn Bioventures, Bioqube Ventures, Eight Roads Ventures, F-Prime Capital, Invus, Janus Henderson Investors, Omega Funds, Piper Heartland Healthcare Capital, Premji Invest, Ra Capital Management, Red Tree Venture Capital
Price per Share
$xx.xx
Shares Outstanding
105,595,101
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acorn Bioventures, Bioqube Ventures, Eight Roads Ventures, F-Prime Capital, Invus, Janus Henderson Investors, Omega Funds, Piper Heartland Healthcare Capital, Premji Invest, Ra Capital Management, Red Tree Venture Capital
03/15/2021 Series Seed $81.79MM $xx.xx $136.32MM Biocon
Price per Share
$xx.xx
Shares Outstanding
81,790,144
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Biocon

Bicara Therapeutics Investors Also Invested in These Private Companies

Vedanta Capital
Aisling Capital
Acorn Bioventures
Invus Piper Heartland Healthcare Capital
Braidwell Lp
Bioqube Ventures

Leadership & Board

Leadership

Claire Mazumdar Ph.D
Chief Executive Officer
Ryan Cohlhepp Ph.D
Chief Operating Officer & President
Ivan Hyep
Chief Financial Officer
David Raben MD
Chief Medical Officer

Board

Carolyn Ng Ph.D
TPG
Heath Lukatch Ph.D
Red Tree Venture Capital
Jake Simson Ph.D
RA Capital Management
Ketan Patel MD
F-Prime Capital
Kiran Mazumdar-Shaw
Biocon

Bicara Therapeutics stock FAQs

plusminus

Can you buy Bicara Therapeutics stock?

You can no longer buy Bicara Therapeutics stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Bicara Therapeutics stock?

You can no longer buy Bicara Therapeutics stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Bicara Therapeutics stock?

You can no longer sell stock of Bicara Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Bicara Therapeutics stock?

You can no longer sell stock of Bicara Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is Bicara Therapeutics a public company?

Bicara Therapeutics is now a public company traded on NASDAQ with ticker BCAX.
plusminus

What is Bicara Therapeutics’ stock price?

The stock price of Bicara Therapeutics is not currently available.
plusminus

What is Bicara Therapeutics’ stock ticker symbol?

The ticker symbol of Bicara Therapeutics is BCAX.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Bicara Therapeutics News and Media Highlights

Bicara nets second nine-digit haul in nine months, raising $165M series C

Venture capitalists and biotech CEOs have been largely speaking with one voice this year with respect to the state of new financing, underscoring that the only thing that matters is having enough money to last until the next catalyst. Bicara Therapeutics is acting on that advice, closing a $165 million series C just nine months after raising a $108 million series B. The new round is quadruple the $40 million secured by Bicara when it launched in 2021.
Browse Insights
Updated on: Dec 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.